BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 11:04:08 2024-06-26 EDT | ||
| 7.148 EUR | -5.61% |
|
| Current month | +48.42% | ||
| 1 month | +35.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 7.148 | -5.61% |
| 24-06-25 | 7.573 | +15.11% |
| 24-06-24 | 6.579 | -1.38% |
| 24-06-21 | 6.671 | -1.75% |
| 24-06-20 | 6.79 | +5.68% |
Real-time Euronext Paris
Last update June 26, 2024 at 11:04 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| FW98S | |
| ISIN | DE000SW7SJK8 |
| Date issued | 2024-03-15 |
| Strike | 745.7 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 5.11 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.957 € |
|---|---|
| Lowest since issue | 2.635 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
938.1
DKK
Spread / Average Target
-6.84%
- Stock Market
- Certificates
- FW98S Certificat
